The Fraunhofer-Gesellschaft, on behalf of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, has signed an asset transfer agreement with Takeda GmbH to exclusively transfer its Surfactant and Continuous Powder Aerosolization (CPA) program assets to Fraunhofer ITEM.
The transfer includes the CPA technology for continuous aerosolization of powdery substances and the know-how to manufacture recombinant surfactant protein C, together with the associated intellectual property. The Fraunhofer ITEM is thus in a position to continue the development of therapies involving continuous inhalation various medications, begun 10 years ago.
Closing down its respiratory department, Takeda transferred its Surfactant and CPA program assets to Fraunhofer ITEM including the associated intellectual property. The CPA technology is the first non-invasive administration method for powdery surfactant drugs.
Surfactant drugs have to be administered to patients with surfactant deficiency, which is common, for example, in preterm in neonates. Furthermore, this therapeutic approach has been investigated in other acute and chronic life-threatening diseases such as acute lung injury and COPD.
Surfactant (“surface-active agent“) is secreted by certain lung cells und reduces surface tension in the alveoli, thereby preventing their collapse. Physical activity causes an increase, smoking a decrease in surfactant production. Fetal surfactant production starts in week 24 of gestation. Preterm neonates, in particular if born before week 34 of gestation, suffer from varying degrees of pulmonary surfactant deficiency, which may lead to neonate respiratory distress syndrome.
Surfactant-based therapy is the standard of care. Its use is limited, however, due to the currently invasive administration methodology. The CPA technology simplifies surfactant delivery to neonates and can also be used for children and adults. Recombinant surfactant protein C is the first recombinant surfactant protein suitable for use in synthetic surfactant drugs.
CPA is also a suitable technology to continuously deliver pulmonary high doses of non-soluble drugs to patients. In respiratory care, the standard of aerosolization for continuous inhalation is currently confined to different classes of nebulizers. In contrast, the CPA technology for the first time enables continuous inhaled administration of non-soluble drugs. In addition, it delivers a higher drug concentration to patients and enables a higher lung deposition rate.
Dr. Gerhard Pohlmann, Head of Medical Inhalation Technology at Fraunhofer ITEM with a 10+ year track record in CPA technology development, said: “As a long-standing partner in the CPA program, Fraunhofer ITEM is delighted to continue development of the surfactant and CPA technology platform. We are currently in the strategic process of reorganizing the program and selecting development partners.”
Dr. Gerhard Pohlmann; +49 511 5350-116
Dr. Cathrin Nastevska; +49 511 5350-225
The text of this press release can be found on our homepage at
Dr. Cathrin Nastevska | Fraunhofer Institute for Toxicology and Experimental Medicine
Visualizing gene expression with MRI
23.12.2016 | California Institute of Technology
Illuminating cancer: Researchers invent a pH threshold sensor to improve cancer surgery
21.12.2016 | UT Southwestern Medical Center
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences